A federal judge has certified a class of blood banks and hospitals that are bringing antitrust claims against two major manufacturers of blood reagents.

One manufacturer, Immucor, which had a 55 percent market share, is settling with the dozens of plaintiffs for $22 million. Jeffrey J. Corrigan, who represents the class, said he expects final approval of the settlement early next month.